FDG PET/CT显像在免疫治疗淋巴瘤患者结局预测与疗效评估中的价值:一项Meta分析与系统综述
该Meta分析与系统综述检索PubMed数据库,最终纳入91篇文献,评估18F-FDG PET/CT在抗CD20抗体、免疫检查点抑制剂及免疫细胞治疗淋巴瘤患者中的结局预测与疗效评估价值。抗CD20治疗中,基线MTV对PFS的汇总HR最高,早期SUVmax和后期DS对PFS的汇总HR最高;DS在早期和后期评估中对PFS和OS的HR均高于IHP视觉标准。ICI和细胞治疗的早期及后期18F-FDG PET/CT疗效评估可能有效预测临床结局。
要点
- 抗CD20治疗中,基线MTV对PFS的汇总HR为3.19(95%CI 2.36-4.30),对OS的汇总HR为4.39(95%CI 2.71-7.08)。
- 抗CD20治疗中,早期SUVmax对PFS的汇总HR为3.25(95%CI 2.08-5.08),早期DS对OS的汇总HR为3.23(95%CI 1.87-5.58)。
- 抗CD20治疗中,后期DS对PFS和OS的汇总HR分别为3.73(95%CI 2.50-5.56)和3.64(95%CI 1.40-9.43)。
核心结论
- 对于淋巴瘤抗CD20治疗,基线18F-FDG PET/CT衍生参数MTV对PFS和OS具有最高的HR。
- 抗CD20治疗中,早期和后期疗效评估采用DS视觉标准对PFS和OS的HR高于国际协调项目(IHP)视觉标准。
- 早期18F-FDG PET参数变化可能预测淋巴瘤患者对ICI和细胞治疗的应答。
研究设计与样本
- 本研究为Meta分析与系统综述,检索PubMed数据库,初始识别1488篇论文,最终纳入91篇。
- 纳入标准为:针对不同类型恶性淋巴瘤患者的临床研究;接受抗CD20抗体、免疫检查点抑制剂或免疫细胞治疗;以18F-FDG作为PET示踪剂行PET/CT。
主要发现
- 抗CD20治疗中,基线、早期和后期疗效监测参数对PFS的汇总HR最高者分别为MTV 3.19(95%CI 2.36-4.30)、SUVmax 3.25(95%CI 2.08-5.08)和DS 3.73(95%CI 2.50-5.56)。
- 抗CD20治疗中,上述参数对OS的汇总HR最高者分别为MTV 4.39(95%CI 2.71-7.08)、DS 3.23(95%CI 1.87-5.58)和DS 3.64(95%CI 1.40-9.43)。
- ICI和免疫细胞治疗的早期及后期18F-FDG PET/CT疗效评估可能是预测临床结局的有效工具。
关键数值与推荐
- 抗CD20治疗中,基线MTV对PFS的汇总HR为3.19(95%CI 2.36-4.30),对OS的汇总HR为4.39(95%CI 2.71-7.08)。
- 抗CD20治疗中,早期SUVmax对PFS的汇总HR为3.25(95%CI 2.08-5.08),早期DS对OS的汇总HR为3.23(95%CI 1.87-5.58)。
- 抗CD20治疗中,后期DS对PFS的汇总HR为3.73(95%CI 2.50-5.56),对OS的汇总HR为3.64(95%CI 1.40-9.43)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Treatment strategies of lymphoid malignancies have been revolutionized by immunotherapy. Because of the inherent property of Hodgkin lymphoma and some subtypes of non-Hodgkin lymphoma as a highly FDG-avid tumor, functional 18F-FDG PET/CT imaging is already embedded in their routine care. Nevertheless, the question is whether it is still valuable in the context of these tumors being treated with immunotherapy. Herein, we will review the value of 18F-FDG PET/CT imaging lymphoid tumors treated with immunotherapy regimens. METHODS: A comprehensive literature search of the PubMed database was conducted on the value of the 18F-FDG PET/CT for immunotherapy response monitoring of patients with malignant lymphoma. The articles were considered eligible if they met all of the following inclusion criteria: (a) clinical studies on patients with different types of malignant lymphoma, (b) treatment with anti-CD20 antibodies, immune checkpoint inhibitors or immune cell therapies, (c) and incorporated PET/CT with 18F-FDG as the PET tracer. RESULTS: From the initial 1488 papers identified, 91 were ultimately included in our study. In anti-CD20 therapy, the highest pooled hazard ratios (HRs) of baseline, early, and late response monitoring parameters for progression-free survival (PFS) belong to metabolic tumor volume (MTV) (3.19 (95%CI: 2.36-4.30)), maximum standardized uptake value (SUVmax) (3.25 (95%CI: 2.08-5.08)), and Deauville score (DS) (3.73 (95%CI: 2.50-5.56)), respectively. These measurements for overall survival (OS) were MTV (4.39 (95%CI: 2.71-7.08)), DS (3.23 (95%CI: 1.87-5.58)), and DS (3.64 (95%CI: 1.40-9.43)), respectively. Early and late 18F-FDG PET/CT response assessment in immune checkpoint inhibitors (ICI) and immune cell therapy might be an effective tool for prediction of clinical outcome. CONCLUSION: For anti-CD20 therapy of lymphoma, the MTV as a baseline 18F-FDG PET/CT-derived parameter has the highest HRs for PFS and OS. The DS as visual criteria in early and late response assessment has higher HRs for PFS and OS compared to the international harmonization project (IHP) visual criteria in anti-CD20 therapy. Early changes in 18F-FDG PET parameters may be predictive of response to ICIs and cell therapy in lymphoma patients.
引用
- Kiamanesh Z, Ayati N, Sadeghi R, et al. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2022. PMID: 35932329. doi:10.1007/s00259-022-05918-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。